

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/011436 A1

(51) International Patent Classification⁷: C07D 215/22, A61K 31/47, A61P 31/06, C07D 409/06, 215/36, 405/06, 401/06, 405/04, 215/48, 409/04, 401/12, 471/04 // (C07D 471/04, 235:00, 221:00)

(21) International Application Number:
PCT/EP2003/050322

(22) International Filing Date: 18 July 2003 (18.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/398,711 25 July 2002 (25.07.2002) US

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BÉ]; Turnhoutseweg 30, B-2340 Beerse (BE).

(71) Applicant and

(72) Inventor: GUILLEMONT, Jérôme, Emile, Georges [FR/FR]; C/O Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VAN GESTEL,

Jozef, Frans, Elisabetha [BE/BÉ]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VENET, Marc, Gaston [FR/FR]; 10, Square de Bourgogne, F-76240 Le Mesnil-Esnard (FR). POIGNET, Hervé, Jean, Joseph [FR/FR]; C/O Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). DECRANE, Laurence, Françoise, Bernadette [FR/FR]; C/O Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). VERNIER, Daniel, F., J. [FR/FR]; C/O Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR).



(74) Common Representative: JANSSEN PHARMACEUTICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

{Continued on next page}

(54) Title: QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS



(57) Abstract: The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as *Mycobacterium tuberculosis*, *M. bovis*, *M. avium* and *M. marinum*. In particular, compounds are claimed in which, independently from each other, R¹ is bromo, p=1, R² is alkoxy, R³ is optionally substituted naphthyl or phenyl, q=1, R⁴ and R⁵ each independently are hydrogen, methyl or ethyl, R⁶ is hydrogen, r is equal to 0 or 1 and R⁷ is hydrogen. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.

WO 2004/011436 A1



SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
- *of inventorship (Rule 4.17(iv)) for US only*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS

5 The present invention relates to novel substituted quinoline derivatives useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as *Mycobacterium tuberculosis*, *M. bovis*, *M. avium* and *M. marinum*.

10

BACKGROUND OF THE INVENTION

Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), a serious and potentially fatal infection with a world-wide distribution. Estimates from the World Health Organization indicate that more than 8 million people contract TB each year, 15 and 2 million people die from tuberculosis yearly. In the last decade, TB cases have grown 20% worldwide with the highest burden in the most impoverished communities. If these trends continue, TB incidence will increase by 41% in the next twenty years. Fifty years since the introduction of an effective chemotherapy, TB remains after 20 AIDS, the leading infectious cause of adult mortality in the world. Complicating the TB epidemic is the rising tide of multi-drug- resistant strains, and the deadly symbiosis with HIV. People who are HIV-positive and infected with TB are 30 times more likely to develop active TB than people who are HIV-negative and TB is responsible for the death of one out of every three people with HIV/AIDS worldwide

25 Existing approaches to treatment of tuberculosis all involve the combination of multiple agents . For example, the regimen recommended by the U.S. Public Health Service is a combination of isoniazid, rifampicin and pyrazinamide for two months, followed by isoniazid and rifampicin alone for a further four months. These drugs are continued for a further seven months in patients infected with HIV. For patients infected with multi- 30 drug resistant strains of *M. tuberculosis*, agents such as ethambutol, streptomycin, kanamycin, amikacin, capreomycin, ethionamide, cycloserine, ciprofloxacin and ofloxacin are added to the combination therapies. There exists no single agent that is effective in the clinical treatment of tuberculosis, nor any combination of agents that offers the possibility of therapy of less than six months' duration.

35

There is a high medical need for new drugs that improve current treatment by enabling regimens that facilitate patient and provider compliance. Shorter regimens and those that require less supervision are the best way to achieve this. Most of the benefit from

treatment comes in the first 2 months, during the intensive, or bactericidal, phase when four drugs are given together; the bacterial burden is greatly reduced, and patients become noninfectious. The 4- to 6-month continuation, or sterilizing, phase is required to eliminate persisting bacilli and to minimize the risk of relapse. A potent sterilizing drug that shortens treatment to 2 months or less would be extremely beneficial. Drugs that facilitate compliance by requiring less intensive supervision also are needed. Obviously, a compound that reduces both the total length of treatment and the frequency of drug administration would provide the greatest benefit.

5 Complicating the TB epidemic is the increasing incidence of multi-drug- resistant strains or MDR-TB. Up to four percent of all cases worldwide are considered MDR-TB - those resistant to the most effective drugs of the four-drug standard, isoniazid and rifampin. MDR-TB is lethal when untreated and can not be adequately treated through the standard therapy, so treatment requires up to 2 years of "second-line" drugs. These 15 drugs are often toxic, expensive and marginally effective. In the absence of an effective therapy, infectious MDR-TB patients continue to spread the disease, producing new infections with MDR-TB strains. There is a high medical need for a new drug with a new mechanism of action, which is likely to demonstrate activity against MDR strains.

10 The purpose of the present invention is to provide novel compounds, in particular substituted quinoline derivatives, having the property of inhibiting growth of mycobacteria and therefore useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as *Mycobacterium tuberculosis*, *M. bovis*, *M. avium* and *M. marinum*.

20 Substituted quinolines were already disclosed in US 5,965,572 (The United States of America) for treating antibiotic resistant infections and in WO 00/34265 to inhibit the growth of bacterial microorganisms. None of these publications disclose the substituted quinoline derivatives according to our invention.



25

30


SUMMARY OF THE INVENTION

35 The present invention relates to novel substituted quinoline derivatives according to Formula (Ia) or Formula (Ib)

-3-



the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, wherein :

10	R ¹	is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ;
	p	is an integer equal to zero, 1, 2, 3 or 4 ;
	R ²	is hydrogen, hydroxy, thio, alkyloxy, alkyloxyalkyloxy, alkylthio, mono  or di(alkyl)amino or a radical of formula
	O, S, NH or N-alkyl ;	wherein Y is CH ₂ ,
15	R ³	is alkyl, Ar, Ar-alkyl, Het or Het-alkyl;
	q	is an integer equal to zero, 1, 2, 3 or 4 ;
	R ⁴ and R ⁵	each independently are hydrogen, alkyl or benzyl; or
	R ⁴ and R ⁵ together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, 2H-pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, imidazolidinyl, pyridazinyl, pyrimidinyl, pyrazinyl,	

triazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, amino, mono- or dialkylamino, alkylthio, alkyloxyalkyl, alkylthioalkyl and pyrimidinyl ;

5 R^6 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ; or

two vicinal R^6 radicals may be taken together to form a bivalent radical of formula $=C-C=C=C-$;

10 r is an integer equal to 0, 1, 2, 3, 4 or 5 ; and

R^7 is hydrogen, alkyl, Ar or Het ;

15 R^8 is hydrogen or alkyl ;

R^9 is oxo ; or

R^8 and R^9 together form the radical $=N-CH=CH-$.

$alkyl$ is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; or is a a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with halo, hydroxy, alkyloxy or oxo ;

20 Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl ;

25 Het is a monocyclic heterocycle selected from the group of N-phenoxy piperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]dioxolyl ; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 substituents selected from the group of halo, hydroxy, alkyl or alkyloxy ;

30 halo is a substituent selected from the group of fluoro, chloro, bromo and iodo and

35 haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, wherein one or more carbon atoms are substituted with one or more halo-atoms.

The compounds according to Formula (Ia) and (Ib) are interrelated in that e.g. a compound according to Formula (Ib), with R^9 equal to oxo is the tautomeric equivalent of a compound according to Formula (Ia) with R^2 equal to hydroxy (keto-enol 5 tautomerism).

DETAILED DESCRIPTION

In the framework of this application, alkyl is a straight or branched saturated 10 hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with halo, hydroxy, alkyloxy or oxo. 15 Preferably, alkyl is methyl, ethyl or cyclohexylmethyl.


In the framework of this application, Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, 20 halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl. Preferably, Ar is naphthyl or phenyl, each optionally substituted with 1 or 2 halo substituents.

25 In the framework of this application, Het is a monocyclic heterocycle selected from the group of N-phenoxyperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxaliny, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, 30 benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]dioxolyl ; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 substituents selected from the group of halo, hydroxy, alkyl or alkyloxy. Preferably, Het is thienyl.

35 In the framework of this application, halo is a substituent selected from the group of fluoro, chloro, bromo and iodo and haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, wherein one or more carbon atoms are

substituted with one or more halo-atoms. Preferably, halo is bromo, fluoro or chloro and preferably, haloalkyl is trifluoromethyl.

Preferably, the invention relates to compounds of Formula (Ia) and (Ib) wherein :

5 R^1 is hydrogen, halo, cyano, Ar, Het, alkyl, and alkyloxy ;
 p is an integer equal to zero, 1, 2, 3 or 4 ;
 R^2 is hydrogen, hydroxy, alkyloxy, alkyloxyalkyloxy, alkylthio or a radical

 of formula wherein Y is O ;

10 R^3 is alkyl, Ar, Ar-alkyl or Het ;
 q is an integer equal to zero, 1, 2, or 3 ;
 R^4 and R^5 each independently are hydrogen, alkyl or benzyl; or
 R^4 and R^5 together and including the N to which they are attached may form a radical
 selected from the group of pyrrolidinyl, imidazolyl, triazolyl,
 piperidinyl, piperazinyl, pyrazinyl, morpholinyl and thiomorpholinyl,
 15 optionally substituted with alkyl and pyrimidinyl ;
 R^6 is hydrogen, halo or alkyl ; or
 two vicinal R^6 radicals may be taken together to form a bivalent radical of formula
 $=C-C=C=C-$;
 r is an integer equal to 1 ; and

20 R^7 is hydrogen ;
 R^8 is hydrogen or alkyl ;
 R^9 is oxo ; or
 R^8 and R^9 together form the radical $=N-CH=CH-$.

25 alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6
 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6
 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6
 carbon atoms attached to a straight or branched saturated hydrocarbon radical
 having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally
 substituted with halo or hydroxy ;

30 Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl,
 tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each
 substituent independently selected from the group of halo, haloalkyl, cyano,
 alkyloxy and morpholinyl ;

35 Het is a monocyclic heterocycle selected from the group of N-phenoxy piperidinyl,
 furanyl, thienyl, pyridinyl, pyrimidinyl ; or a bicyclic heterocycle selected from

the group of benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]-dioxolyl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 alkyl substituents ; and
halo is a substituent selected from the group of fluoro, chloro and bromo.

5

For compounds according to either Formula (Ia) and (Ib), preferably, R¹ is hydrogen, halo, Ar, alkyl or alkyloxy. More preferably, R¹ is halo. Most preferably, R¹ is bromo.

Preferably, p is equal to 1.

10

Preferably, R² is hydrogen, alkyloxy or alkylthio. More preferably, R² is alkyloxy. Most preferably, R² is methyloxy.

15

Preferably, R³ is naphthyl, phenyl or thiienyl, each optionally substituted with 1 or 2 substituents, that substituent preferably being a halo or haloalkyl, most preferably being a halo. More preferably, R³ is naphthyl or phenyl. Most preferably, R³ is naphthyl.

Preferably, q is equal to zero, 1 or 2. More preferably, q is equal to 1.

20

Preferably, R⁴ and R⁵ each independently are hydrogen or alkyl, more preferably hydrogen, methyl or ethyl, most preferably methyl.

25

Preferably R⁴ and R⁵ together and including the N to which they are attached form a radical selected from the group of imidazolyl, triazolyl, piperidinyl, piperazinyl and thiomorpholinyl, optionally substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, alkylthio, alkyloxyalkyl or alkylthioalkyl, preferably substituted with alkyl, most preferably substituted with methyl or ethyl.

30

Preferably, R⁶ is hydrogen, alkyl or halo. Most preferably, R⁶ is hydrogen. Preferably r is 0, 1 or 2.

Preferably, R⁷ is hydrogen or methyl.

35

For compounds according to Formula (Ib) only, preferably, R⁸ is alkyl, preferably methyl and R⁹ is oxygen.

An interesting group of compounds are those compounds according to Formula (Ia), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically

isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, in which R¹ is hydrogen, halo, Ar, alkyl or alkyloxy, p = 1, R² is hydrogen, alkyloxy or alkylthio, R³ is naphthyl, phenyl or thienyl, each optionally substituted with 1 or 2 substituents selected from the group of halo and haloalkyl, q = 0, 1, 2 or 3, R⁴ and R⁵ each independently are hydrogen or alkyl or R⁴ and R⁵ together and including the N to which they are attached form a radical selected from the group of imidazolyl, triazolyl, piperidinyl, piperazinyl and thiomorpholinyl, R⁶ is hydrogen, alkyl or halo, r is equal to 0 or 1 and R⁷ is hydrogen.

10 Most preferable, the compound is :

- o 1-(6-bromo-2-methoxy-quinolin-3-yl)-2-(3,5-difluoro-phenyl)-4-dimethylamino-1-phenyl-butan-2-ol ;
- o 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol ;
- o 1-(6-bromo-2-methoxy-quinolin-3-yl)-2-(2,5-difluoro-phenyl)-4-dimethylamino-1-phenyl-butan-2-ol ;
- o 1-(6-bromo-2-methoxy-quinolin-3-yl)-2-(2,3-difluoro-phenyl)-4-dimethylamino-1-phenyl-butan-2-ol ;
- o 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-(2-fluoro-phenyl)-1-phenyl-butan-2-ol ;
- o 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol ; and
- o 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-(3-fluoro-phenyl)-1-phenyl-butan-2-ol,

the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof.

30

The pharmaceutically acceptable acid addition salts are defined to comprise the therapeutically active non-toxic acid addition salt forms which the compounds according to either Formula (Ia) and (Ib) are able to form. Said acid addition salts can be obtained by treating the base form of the compounds according to either Formula (Ia) and (Ib) with appropriate acids, for example inorganic acids, for example hydrohalic acid, in particular hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid ; organic acids, for example acetic acid, hydroxyacetic acid, propionic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid,

maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclamic acid, salicyclic acid, p-aminosalicylic acid and pamoic acid.

5 The compounds according to either Formula (Ia) and (Ib) containing acidic protons may also be converted into their therapeutically active non-toxic base addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salts forms comprise, for example, the ammonium salts, the alkaline and earth alkaline metal salts, in particular lithium, sodium, potassium, magnesium and calcium salts,

0 salts with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, hybramine salts, and salts with amino acids, for example arginine and lysine.

Conversely, said acid or base addition salt forms can be converted into the free forms by treatment with an appropriate base or acid.

5 The term addition salt as used in the framework of this application also comprises the solvates which the compounds according to either Formula (Ia) and (Ib) as well as the salts thereof, are able to form. Such solvates are, for example, hydrates and alcoholates.

10 The term "stereochemically isomeric forms" as used herein defines all possible isomeric forms which the compounds of either Formula (Ia) and (Ib) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans- configuration. Stereochemically isomeric forms of the compounds of either Formula (Ia) and (Ib) are obviously intended to be embraced within the scope of this invention.

15 30 Following CAS-nomenclature conventions, when two stereogenic centers of known absolute configuration are present in a molecule, an R or S descriptor is assigned (based on Cahn-Ingold-Prelog sequence rule) to the lowest-numbered chiral center, the reference center. The configuration of the second stereogenic center is indicated using relative descriptors [R*,R*] or [R*,S*], where R* is always specified as the reference center and [R*,R*] indicates centers with the same chirality and [R*,S*] indicates centers of unlike chirality. For example, if the lowest-numbered chiral center in the molecule has an S configuration and the second center is R, the stereo descriptor would

be specified as $S-[R^*,S^*]$. If “ α ” and “ β ” are used : the position of the highest priority substituent on the asymmetric carbon atom in the ring system having the lowest ring number, is arbitrarily always in the “ α ” position of the mean plane determined by the ring system. The position of the highest priority substituent on the other asymmetric carbon atom in the ring system relative to the position of the highest priority substituent on the reference atom is denominated “ α ”, if it is on the same side of the mean plane determined by the ring system, or “ β ”, if it is on the other side of the mean plane determined by the ring system.

10 Compounds of either Formula (Ia) and (Ib) and some of the intermediate compounds invariably have at least two stereogenic centers in their structure which may lead to at least 4 stereochemically different structures.


15 The tautomeric forms of the compounds of either Formula (Ia) and (Ib) are meant to comprise those compounds of either Formula (Ia) and (Ib) wherein e.g. an enol group is converted into a keto group (keto-enol tautomerism).

20 The N -oxide forms of the compounds according to either Formula (Ia) and (Ib) are meant to comprise those compounds of either Formula (Ia) and (Ib) wherein one or several nitrogen atoms are oxidized to the so-called N -oxide, particularly those N -oxides wherein the nitrogen of the amine radical is oxidized.

25 The compounds of either Formula (Ia) and (Ib) as prepared in the processes described below may be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of either Formula (Ia) and (Ib) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of either Formula (Ia) and (Ib) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The invention also comprises derivative compounds (usually called "pro-drugs") of the pharmacologically-active compounds according to the invention, which are degraded *in vivo* to yield the compounds according to the invention. Pro-drugs are usually (but not always) of lower potency at the target receptor than the compounds to which they are degraded. Pro-drugs are particularly useful when the desired compound has chemical or physical properties that make its administration difficult or inefficient. For example, the desired compound may be only poorly soluble, it may be poorly transported across the mucosal epithelium, or it may have an undesirably short plasma half-life. Further discussion on pro-drugs may be found in Stella, V. J. *et al.*, "Prodrugs", *Drug Delivery Systems*, 1985, pp. 112-176, and *Drugs*, 1985, 29, pp. 455-473.

Pro-drugs forms of the pharmacologically-active compounds according to the invention will generally be compounds according to either Formula (Ia) and (Ib), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, having an acid group which is esterified or amidated. Included in such esterified acid groups are groups of the formula $-\text{COOR}^x$, where R^x is a C_{1-6} alkyl, phenyl, benzyl or one of the following groups :



20

Amidated groups include groups of the formula $-\text{CONR}^y\text{R}^z$, wherein R^y is H, C_{1-6} alkyl, phenyl or benzyl and R^z is $-\text{OH}$, H, C_{1-6} alkyl, phenyl or benzyl.

Compounds according to the invention having an amino group may be derivatised with a ketone or an aldehyde such as formaldehyde to form a Mannich base. This base will hydrolyze with first order kinetics in aqueous solution.

The compounds according to the invention have surprisingly been shown to be suitable for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as *Mycobacterium tuberculosis*, *M. bovis*, *M. avium* and *M. marinum*. The present invention thus also relates to compounds of either Formula (Ia) and (Ib) as defined hereinabove, the pharmaceutically acceptable acid or base

addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, for use as a medicine.

The invention also relates to a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to the invention. The compounds according to the invention may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, in particular, for administration orally or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.

Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 % by weight, more preferably from 0.1 to 70 % by weight of the active ingredient, and, from 1 to 99.95 % by weight, more preferably from 30 to 99.9 weight % of a pharmaceutically acceptable carrier, all percentages being based on the total composition.

The pharmaceutical composition may additionally contain various other ingredients known in the art, for example, a lubricant, stabilising agent, buffering agent, emulsifying agent, viscosity-regulating agent, surfactant, preservative, flavouring or colorant.

5

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated

10 to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof. The daily dosage of the compound according to the invention will, of course, vary with
15 the compound employed, the mode of administration, the treatment desired and the mycobacterial disease indicated. However, in general, satisfactory results will be obtained when the compound according to the invention is administered at a daily dosage not exceeding 1gram, e.g. in the range from 10 to 50 mg/kg body weight.

20 Further, the present invention also relates to the use of a compound of either Formula (Ia) and (Ib), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, as well as any of the aforementioned pharmaceutical compositions thereof for the manufacture of a medicament for the treatment of mycobacterial
25 diseases.


Accordingly, in another aspect, the invention provides a method of treating a patient suffering from, or at risk of, a mycobacterial disease, which comprises administering to the patient a therapeutically effective amount of a compound or pharmaceutical
30 composition according to the invention.

GENERAL PREPARATION

35 The compounds according to the invention can generally be prepared by a succession of steps, each of which is known to the skilled person.

In particular, the compounds according to Formula (Ia) can be prepared by reacting an intermediate compound of Formula (II) with an intermediate compound of Formula (III) according to the following reaction scheme (1) :


5

Scheme 1

using BuLi in a mixture of DIPA and THF, wherein all variables are defined as in Formula (Ia). Stirring may enhance the rate of the reaction. The reaction may

10 conveniently be carried out at a temperature ranging between -20 and -70 °C.

The starting materials and the intermediate compounds of Formula (II) and (III) are compounds that are either commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example,
 15 intermediate compounds of Formula (II-a) may be prepared according to the following reaction scheme (2):

Scheme 2


wherein all variables are defined as in Formula (Ia) and (Ib). Reaction scheme (2) comprises step (a) in which an appropriately substituted aniline is reacted with an appropriate acylchloride such as 3-phenylpropionyl chloride, 3-fluorobenzenepropionyl chloride or p-chlorobenzenepropionyl chloride, in the presence of a suitable base, such as triethylamine and a suitable reaction-inert solvent, such as methylene chloride or ethylene dichloride. The reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature. In a next step (b) the adduct obtained in step (a) is reacted with phosphoryl chloride (POCl_3) in the presence of N,N -dimethylformamide (Vilsmeier-Haack formylation followed by cyclization).

10 The reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature. In a next step (c) a specific R^3 -group, wherein R^3 is an alkyloxy or alkylthio radical is introduced by reacting the intermediate compound obtained in step (b) with a compound X-Alk , wherein $\text{X}=\text{S}$ or O and Alk is an alkylgroup as defined in Formula (Ia) and (Ib).

15

Intermediate compounds according to Formula (II-b) may be prepared according to the following reaction scheme (3), wherein in a first step (a) a substituted indole-2,3-dione is reacted with a substituted 3-phenylpropionaldehyde in the presence of a suitable base such as sodium hydroxide (Pfitzinger reaction), after which the carboxylic acid compound in a next step (b) is decarboxylated at high temperature in the presence of a suitable reaction-inert solvent usch as diphenylether.

Scheme 3




25

It is evident that in the foregoing and in the following reactions, the reaction products

may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art, such as extraction, crystallization and chromatography. It is further evident that reaction products that exist in more than one enantiomeric form, may be isolated from their mixture by known techniques, in 5 particular preparative chromatography, such as preparative HPLC. Typically, compounds of Formula (Ia) and (Ib) may be separated into their isomeric forms.

The intermediate compounds of Formula (III) are compounds that are either 10 commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example, intermediate compounds of Formula (III-a) in which R^3 is Ar substituted with s substituents R^{10} , wherein each R^{10} is independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl and s is an integer 15 equal to zero, 1, 2 or 3, may be prepared according to the following reaction scheme (4):

Scheme 4



Reaction scheme (4) comprises step (a) in which an appropriately substituted phenyl is 25 reacted by Friedel-Craft reaction with an appropriate acylchloride such as 3-chloropropionyl chloride or 4-chlorobutyryl chloride, in the presence of a suitable Lewis acid, such as AlCl_3 , FeCl_3 , SnCl_4 , TiCl_4 or ZnCl_2 and a suitable reaction-inert solvent, such as methylene chloride or ethylene dichloride. The reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature. In a next step (b) an amino group ($-\text{NR}_4\text{R}_5$) is introduced by reacting the intermediate compound obtained in step (a) with a primary or secondary 30 amine.

The following examples illustrate the present invention without being limited thereto.

EXPERIMENTAL PART


Of some compounds the absolute stereochemical configuration of the stereogenic carbon atom(s) therein was not experimentally determined. In those cases the 5 stereochemically isomeric form which was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration. However, said "A" and "B" isomeric forms can be unambiguously characterized by a person skilled in the art, using art-known methods such as, for example, X-ray diffraction. The isolation method is described in detail below.

10

Hereinafter, "DMF" is defined as *N,N*-dimethylformamide, "DIPE" is defined as diisopropyl ether, "THF" is defined as tetrahydrofuran.


A. Preparation of the intermediate compoundsExample A1

Preparation of intermediate compound 1



20 Benzene propanoylchloride (0.488 mol) was added dropwise at room temperature to a solution of 4-bromobenzenamine (0.407 mol) in Et₃N (70ml) and CH₂Cl₂ (700ml) and the mixture was stirred at room temperature overnight. The mixture was poured out into water and concentrated NH₄OH, and extracted with CH₂Cl₂. The organic layer was dried (MgSO₄), filtered, and the solvent was evaporated. The residue was crystallized from diethyl ether. The residue (119.67g) was taken up in CH₂Cl₂ and washed with HCl 1N. The organic layer was dried (MgSO₄), filtered, and the solvent was evaporated. Yielding: 107.67g of intermediate compound 1.


Preparation of intermediate compound 9



25 Accordingly, intermediate compound 9 was prepared in the same way as intermediate compound 1 but using 4-methylbenzene propanoylchloride.


Example A2

Preparation of intermediate compound 2



The reaction was carried out twice . POCl_3 (1.225 mol) was added dropwise at 10°C to DMF (0.525 mol) . Then intermediate compound 1 (prepared according A1) (0.175 mol) was added at room temperature . The mixture was stirred overnight at 80°C, poured out on ice and extracted with CH_2Cl_2 . The organic layer was dried (MgSO_4), 5 filtered, and the solvent was evaporated . The product was used without further purification. Yielding: (77.62g; Yield=67%) .

Preparation of intermediate compound 10




Accordingly, intermediate compound 10 was prepared in the same way as intermediate compound 2, starting from intermediate compound 9 (prepared according to A1).

10

Example A3

Preparation of intermediate compound 3




15

A mixture of intermediate compound 2 (prepared according to A2) (0.233 mol) in CH_3ONa (30%) in methanol (222.32 ml) and methanol (776ml) was stirred and refluxed overnight, then poured out on ice and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated . The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{cyclohexane}$ 20/80 and then 100/0; 20-45 μm). The pure fractions were collected and the solvent was evaporated . Yielding: 25g of intermediate compound 3 (Yield=33%; mp.84°C) as a white powder .

20


Preparation of intermediate compound 11



Accordingly, intermediate compound 11 was prepared in the same way as intermediate compound 3, starting from intermediate compound 10 (prepared according to A2).

Example A4

Preparation of intermediate compound 4




A mixture of intermediate compound 2 (prepared according to A2) (0.045 mol) in NaOEt 21% in ethanol (50ml) and ethanol (150ml) was stirred and refluxed for 12 hours. The mixture was poured out on ice and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated.

5 Yielding: 15.2g of intermediate compound 4 (98%).

Example A5

Preparation of intermediate compound 5




A mixture of 5-bromo-1H-indole-2,3-dione (0.28 mol) in NaOH 3N (650ml) was stirred and heated at 80°C for 30 min, then cooled to room temperature.


10 Benzenepropanal (0.28 mol) was added and the mixture was stirred and refluxed overnight. The mixture was allowed to cool to room temperature and acidified till pH=5 with HOAc. The precipitate was filtered off, washed with H₂O and dried (vacuum). Yielding: 50g of intermediate compound 5 (52%).

15 Example A6

Preparation of intermediate compound 6




A mixture of intermediate compound 5 (prepared according to A5) (0.035 mol) in diphenylether (100ml) was stirred and heated at 300°C for 8 hours, then allowed to cool to room temperature. This procedure was carried out four times. The four mixtures were combined and then purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 100/0, then 99/1). The pure fractions were collected and the solvent was evaporated. Yielding: 25.6g of intermediate compound 6 (61%).

Example A7Preparation of intermediate
compound 7 and 8Intermediate 7 = (A)
Intermediate 8 = (B)

nBuLi 1.6M (0.13 mol) was added dropwise at -10°C under N₂ flow to a mixture of N-(1-methylethyl)-2-propanamine (0.13 mol) in THF (300ml) . The mixture was stirred at -10°C for 20 min and then cooled to -70°C . A solution of intermediate 5 compound 3 (prepared according to A3) (0.1 mol) in THF (300ml) was added dropwise. The mixture was stirred at -70°C for 45 min . A solution of 2-(3-oxo-3-phenylpropyl)-1H-isoindole-1,3(2H)-dione (0.13 mol) in THF (300ml) was added dropwise . The mixture was stirred at -70°C for 1 hour, then brought to -40°C, stirred at -40°C for 2 hours, hydrolyzed at -40°C with H₂O and extracted with EtOAc . The 10 organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated . The residue (40g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 85/15) . Two pure fractions were collected and their solvents were evaporated . Yielding: 1.8g of intermediate compound 7 (3%) and 5.3g of intermediate compound 8 (9%).

15

Example A8Preparation of intermediate
compounds 12 and 13

Intermediate 12


Intermediate 13

A mixture of aluminium chloride (34.3g, 0.257mol) and 3-chloropropionyl chloride (29.7g, 0.234mol) in dichloroethane (150ml) was stirred at 0°C. A solution of napthalene (30g, 0.234mol) in dichloroethane (50ml) was added. The mixture was stirred at 5°C for 2 hours and poured out into ice water. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (56g) was purified by column chromatography over silica gel (eluent: cyclohexane/ CH₂Cl₂: 60/40; 20-45μm). Two fractions were collected and the solvent was evaporated to 20

afford intermediate compound 12 (31g; Yield=61%) as an oil. The second fraction (14g) was taken up in DIPE to afford intermediate compound 13 (8.2g; Yield=16%; mp.68°C) as a pale yellow solid.

5 Example A9

Preparation of intermediate compound 14



Intermediate 14


A mixture of the intermediate compound 12 (prepared according to A8) (3g; 0.0137mol),

10 N-benzylmethyl amine (2ml; 0.0150mol) in acetonitrile (100ml) was stirred at 80°C for 2 hours. At room temperature (RT) water was added. The mixture was extracted with CH_2Cl_2 . The organic layer was separated and dried (MgSO_4), filtered, and the solvent was evaporated. The residue (6g) was purified by column chromatography over silica gel (eluent: CH_2Cl_2 / MeOH: 97/3; 20-45 μm) to afford BB1 (4.2g; quantitative yield) as an oil, yielding intermediate compound 14.

15

Example A10

Preparation of intermediate compound 15




A mixture of 3,5-difluoroacetophenone (commercially available) (25g; 0.16mol), diethylamine hydrochloride (52g; 0.64mol), paraformaldehyde (19g; 0.63mol) in HCl conc (5ml) and ethanol (300ml) was stirred at 80°C for 16 hours. The mixture was

20 evaporated till dryness and the residue was taken up by HCl 3N (50ml). This mixture was extracted with Et_2O (3x30ml). The organic layer was collected and basified with K_2CO_3 (10%aq). The organic layer was dried over MgSO_4 and evaporated. The product, intermediate compound 15 was used without further purification for the next step (23.7g; yield : 69%) as an oil.

B. Preparation of the final compoundsExample B1

Preparation of final compound 1, 2, 3

and 4



Compound 1 (A1)

Compound 2 (A2)


Compound 3 (A)

Compound 4 (B)

nBuLi 1.6M (0.067 mol) was added slowly at -20°C under N₂ flow to a solution of 5 N-(1-methylethyl)-2-propanamine (0.067 mol) in THF (100ml) . The mixture was cooled to -70°C . A solution of intermediate compound 3 (prepared according to A3) (0.122 mol) in THF (200ml) was added slowly . The mixture was stirred at -70°C for 30 min . A solution of 3-(dimethylamino)-1-phenyl-1-propanone (0.146 mol) in THF (100ml) was added slowly . The mixture was stirred at -70°C for 1 hour, then 10 hydrolysed at -30°C with ice water and extracted with EtOAc . The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated . The residue (67g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 99/1/0.1; 20-45μm) . Two pure fractions were collected and their solvents were evaporated . Fraction 1 (7,2g) was crystallized from DIPE . The 15 precipitate was filtered off and dried . Yielding: 6.5g of diastereoisomer A (final compound 3) (mp. 172°C) (10%) as a white solid. Fraction 2 (13g) was crystallized from 2-propanone and diethyl ether . The precipitate was filtered off and dried . Yielding: 11g of diastereoisomer B (final compound 4) (mp.170°C) (17%) as a white solid . Part of fraction of final compound 3 (4g) was separated into its enantiomers by 20 column chromatography (eluent: hexane/2-propanol 99.9/0.1; column: CHIRACEL OD) . Two pure fractions were collected and their solvents were evaporated . The residue was crystallized from pentane . The precipitate was filtered off and dried . Yielding: 0.7g of enantiomer A1 (final compound 1) (mp. 194°C) and 0.6g of enantiomer A2 (final compound 2) (mp. 191°C) as a white solid.

Example B2

Preparation of final compound 5
and 6




Compound 5 (A)
Compound 6 (B)

nBuLi 1.6M (0.048 mol) was added slowly at -20°C to a solution of *N*-(1-methylethyl)-2-propanamine (0.048 mol) in THF (70ml) . The mixture was cooled again to -70°C . A solution of intermediate compound 4 (prepared according to A4) (0.044 mol) in THF (150ml) was added slowly . The mixture was stirred at -70°C for 30 min . A solution of 3-(dimethylamino)-1-phenyl-1-propanone (0.053 mol) in THF (100ml) was added slowly . The mixture was stirred at -70°C for 1 hour, hydrolysed at -30°C with ice water and extracted with EtOAc . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated . The residue (23.5g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 99.5/0.5/0.1; 15-40 μm) . Two pure fractions were collected and their solvents were evaporated . The residue was crystallized from DIPE . The precipitate was filtered off and dried . Yielding: 0.7g of final compound 5 (3%) (mp. 162°C) as a white solid and 1g of final compound 6 (5%) (mp. 74°C) as a white solid.

15

Example B3

Preparation of final compound 7
and 8



Compound 7 (A)
Compound 8 (B)


nBuLi (1.6M) (0.070 mol) was added dropwise at -30°C under N_2 flow to a solution of *N*-(1-methylethyl)-2-propanamine (0.070 mol) in THF (70ml) . The mixture was stirred at -20°C for 30 min, then cooled to -70°C . A solution of intermediate

compound 6 (prepared according to A6) (0.046 mol) in THF (130ml) was added dropwise . The mixture was stirred at -70°C for 45 min . A solution of 3-(dimethylamino)-1-phenyl-1-propanone (0.056 mol) in THF (100ml) was added dropwise . The mixture was stirred at -70°C for 2 hours, hydrolyzed with ice-water and extracted with EtOAc . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated . The residue (23.6g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 99/1/0.1; 15-40 μm) . Two pure fractions were collected and their solvents were evaporated . Fraction 1 (4g) was crystallized from diethyl ether . The precipitate was filtered off and dried .

10 Yielding: 1.7g of final compound 7 (mp. 98°C) (7.6%) . Fraction 2 (3.5g) was crystallized from diethyl ether/EtOAc . The precipitate was filtered off and dried . Yielding: 2.2g of final compound 8 (mp. 180°C) (9.8%) as a white solid.

Example B4

Preparation of final compound 9




15 A mixture of intermediate compound 8 (prepared according to A7) (0.009 mol) and hydrazine (0.01 mol) in ethanol (70ml) was stirred and refluxed for 1 hour . The solvent was evaporated till dryness . The residue was dissolved in CH_2Cl_2 . The organic solution was washed with K_2CO_3 10%, dried (MgSO_4), filtered and the solvent was evaporated . The residue (5g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 97/3/0.1; 15-40 μm) . The pure fractions were collected and the solvent was evaporated . The residue was crystallized from diethyl ether . The precipitate was filtered off and dried . Yielding: 2.6g of final compound 9 (mp. 204°C) (62%) as a pale yellow solid.

20

Example B5


Preparation of final compound 10



CH_3I (0.0033 mol) was added at room temperature to a solution of final compound 4 (prepared according to B1) (0.003 mol) in 2-propanone (15ml) . The precipitate was filtered off and dried . Yielding: 1.2g of final compound 10 (mp. 198°C) (62%) as a pale yellow solid.

Example B6


Preparation of final compound 11



A solution of 3-chloroperoxybenzoic acid (0.0069 mol) in CH_2Cl_2 (35ml) was added dropwise at room temperature to a solution of final compound 4 (prepared according to B1) (0.0069 mol) in CH_2Cl_2 (35ml) . The mixture was stirred at room temperature for 1 hour, washed with K_2CO_3 10%, dried (MgSO_4), filtered and the solvent was evaporated. The residue was crystallized from diethyl ether . The precipitate was filtered off and dried . Yielding: 1.8g of final compound 11 (mp. 208°C) as a white solid.

Example B7

Preparation of final compound 12, 13,
14 and 15




Compound 12 (A1)
Compound 13 (A2)
Compound 14 (A)
Compound 15 (B)

nBuLi 1.6M (0.05 mol) was added slowly at -20°C under N2 flow to a solution of *N*-(1-methylethyl)-2-propanamine (0.05 mol) in THF (80ml) . The mixture was stirred at -20°C for 15 minutes, then cooled to -70°C . A solution of intermediate compound 3 (prepared according to A3) (0.046 mol) in THF (150ml) was added slowly . The mixture was stirred at -70°C for 30 minutes . A solution of 0.055 mol of 3-(dimethylamino)-1-(1-naphthyl)-1-propanone in THF (120ml) was added slowly . The mixture was stirred at -70°C for 3 hours, hydrolyzed at -30°C with ice water and extracted with EtOAc . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated . The residue (29g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$; 99.5/0.5/0.1; 15-35 μm) . Two fractions were collected and the solvent was evaporated . Yielding: 3g fraction 1 and 4.4g of fraction 2 . Fraction 1 and 2 were crystallized separately from DIPE . The precipitate was filtered off and dried, yielding: 2.2g of diastereoisomer A final compound 14 (Yield: 9%; mp.210°C) as a white solid and 4g of diastereoisomer B final compound 15 (Yield: 16%; mp.244°C) as a white solid . To obtain the corresponding enantiomers, diastereoisomer A (final compound 14) was purified by chiral chromatography over silica gel (eluent: hexane//EtOH; 99.95/0.05) . Two fractions were collected and the solvent was evaporated . Yielding: 0.233g of enantiomer A1 (final compound 12) (mp. 118°C) as a white solid and 0.287g of enantiomer A2 (final compound 13) (mp. 120°C) as a white solid.

Example B8

Preparation of final compounds 67,
68, 110 and 111



final compound 110

(A1)


final compound 111

(A2)

nBuLi 1.6M (0.067 mol) was added slowly at -20°C under N₂ flow to a solution of N-(1-methylethyl)-2-propanamine (0.0104 mol) in THF (50ml) . The mixture was 5 cooled to -70°C . A solution of intermediate compound 3 (prepared according to A3) (0.0087 mol) in THF (50ml) was added slowly . The mixture was stirred at -70°C for 30 min . A solution of 3-(dimethylamino)-1-(2,5-difluorophenyl)-1-propanone (0.0122 mol) in THF (20ml) was added slowly . The mixture was stirred at -70°C for 1 hour, then hydrolysed at -30°C with ice water and extracted with EtOAc . The 10 organic layer was separated, dried (MgSO₄), filtered off and the solvent was evaporated . The residue (6.3g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 98/2/0.2; 20-45μm) . Two pure fractions were collected and their solvents were evaporated . Fraction 1 (1.2g) was crystallized from Et₂O . The precipitate was filtered off and dried . Yield: 0.63g of diastereoisomer A 15 (final compound 67)(mp. 60°C; Y=13%) as a white solid . Fraction 2 (1g) was crystallized from diethylether . The precipitate was filtered off and dried . Yield: 0.64g of diastereoisomer B (final compound 68) (mp.208°C; Y=14%). 0.63g of diastereoisomer A were purified by chiracel AD (eluent: heptane/iPrOH 99.95/0.05). Two fractions were collected corresponding to A1 enantiomer (final compound 110, 20 0.13g; mp 167°C) as a white solid and the A2 enantiomer (final compound 111, 0.086g) as an oil.

Example B9

Preparation of final compound 38, 39,
108 and 109



nBuLi 1.6M (0.04 mol) was added slowly at -20°C under N₂ flow to a solution of

5 *N*-(1-methylethyl)-2-propanamine (0.04 mol) in THF (50ml) . The mixture was cooled to -70°C . A solution of intermediate compound 3 (prepared according to A3) (0.037 mol) in THF (100ml) was added slowly . The mixture was stirred at -70°C for 30 min . A solution of 3-(dimethylamino)-1-(3-fluorophenyl)-1-propanone (0.044 mol) in THF (50ml) was added slowly . The mixture was stirred at -70°C for 1 hour, then

10 hydrolyzed at -30°C with ice water and extracted with EtOAc . The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated . The residue (20g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 99.5/0.5/0.1; 15-40μm) . Three pure fractions were collected and their solvents were evaporated . Fraction 1 (2.8g) was crystallized from DIPE .

15 The precipitate was filtered off and dried . Yielding: 1.45g (7%) of diastereoisomer A (final compound 38) (mp.198°C) as a white solid. Fraction 2 (3.4g) was crystallized from DIPE . The precipitate was filtered off and dried . Yielding: 1.55g (8%) of diastereoisomer B (final compound 39) (mp.207°C) as a white solid.


Part of fraction of final compound 38 (1g) was separated into its enantiomers by chiral

20 chromatography (eluent: hexane/2-propanol 99.9/0.1; column: CHIRACEL OD). Two pure fractions were collected and their solvents were evaporated. The residue was crystallized from pentane . The precipitate was filtered off and dried . Yield: 0.3g of enantiomer A1 (final compound 108) (mp. 160°C) as a white solid and 0.26g of enantiomer A2 (final compound 109) (mp. 156°C) as a white solid.

Example B10

Preparation of final compound 71 and


72



nBuLi 1.6M (0.0042 mol) was added slowly at -20°C under N₂ flow to a solution of N-(1-methylethyl)-2-propanamine (0.0042 mol) in THF (20ml) . The mixture was 5 cooled to -70°C . A solution of intermediate compound 9 (prepared according to A1) (0.0038 mol) in THF (50ml) was added slowly . The mixture was stirred at -70°C for 30 min . A solution of 3-(dimethylamino)-1-(1-naphthyl)-1-propanone (0.0059 mol) in THF (20ml) was added slowly . The mixture was stirred at -70°C for 1 hour, then hydrolysed at -30°C with ice water and extracted with EtOAc . The organic layer was 10 separated, dried (MgSO₄), filtered and the solvent was evaporated . The residue (2.2g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 99/1/0.1; 15-40µm) . Two pure fractions were collected and their solvents were evaporated. Fraction 1 (0.17g) was crystallized from Et₂O . The precipitate was filtered off and dried. Yield: 0.05g of diastereoisomer A (final 15 compound 71)(mp.174°C; Yield= 3%) as a white solid. Fraction 2 (0.27g) was crystallized from diethyl ether. The precipitate was filtered off and dried . Yield: 0.053g of diastereoisomer B (final compound 72) (mp.178°C; Yield=4%) as a white solid.

20 Example B11

Preparation of final compound 99




A solution of 3-chloroperoxybenzoic acid (0.0036 mol) in CH₂Cl₂ (10ml) was added dropwise at room temperature to a solution of final compound 12 (enantiomer A1) (prepared according to B7) (0.0069 mol) in CH₂Cl₂ (35ml) . The mixture was stirred at 25 room temperature for 1 hour, washed with K₂CO₃ 10%, dried (MgSO₄), filtered and the solvent was evaporated . The residue was crystallized from diethyl ether . The

precipitate was filtered off and dried . Yielding: 0.16g final compound 99 (mp. 218°C; Y=78%) as a white solid.

Example B12


Preparation of final compound 110



5 nBuLi 1.6M (0.0075 mol) was added slowly at -20°C under N₂ flow to a solution of N-(1-methylethyl)-2-propanamine (0.0075 mol) in THF (30ml) . The mixture was cooled to -70°C . A solution of intermediate compound 3 (prepared according to A3) (0.0062 mol) in THF (20ml) was added slowly . The mixture was stirred at -70°C for 30 min . A solution of 0.0075 mol of intermediate compound 14 (prepared according to Example A9) in THF (10ml) was added slowly . The mixture was stirred at -70°C for 90 minutes, then hydrolysed at -30°C with ice water and extracted with EtOAc . The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated . The residue (3g) was purified by column chromatography over silica gel (eluent: Cyclohexane/EtOAc 90/10; 15-40μm) . The final compound 110 (1.5g ;
10 Yield=38%) was obtained as an oil.
15 Yield=38%) was obtained as an oil.

Example B13

Preparation of final compound 111
and 112



final compound 111 (A)

final compound 112 (B)


20 1-chloroethyl chloroformate (0.25ml, 0.0023mol) was added at room temperature under nitrogen to a solution of the derived 111 (1.5gr, 0.0023mol) in dichloromethane (30ml). The mixture was stirred at 80°C for 1 hour. The solvent was evaporated and the methanol (15ml) was added. The mixture was stirred and refluxed for 30 minutes. After evaporation, the residue (1.49gr) was purified by column chromatography over

silica gel (15-40 μ m). The first fraction collected was crystallized from DIPE to afford (0.168gr; mp. 204°C; Yield=13%) final compound 111 as the A diastereoisomer. The second fraction collected was corresponded to final compound 112 as the B diastereoisomer (0.298g; mp.225°C; Yield=23%).

5

Example B14

Preparation of final compounds 113 and 114



final compound 113

(A)

final compound 114

(B)

nBuLi 1.6M (3.5ml; 0.0056 mol) was added slowly at -20°C under N₂ flow to a solution of *N*-(1-methylethyl)-2-propanamine (770 μ l; 0.0055 mol) in THF (20ml).


10 The mixture was cooled to -70°C . A solution of intermediate compound 3 (prepared according to A3) (1.5g ; 0.0047 mol) in THF (20ml) was added slowly . The mixture was stirred at -70°C for 30 min . A solution of intermediate compound 15 (1g ; 0.0047 mol) in THF (10ml) was added slowly . The mixture was stirred at -70°C for 3 hours, then hydrolysed at -30°C with ice water and extracted with EtOAc . The organic layer was separated, dried (MgSO₄), filtered off and the solvent was evaporated . The residue (2.8g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 99/1/0.1; 15-40 μ m) . Two pure fractions were collected and their solvents were evaporated . Fraction 1 (0.149g) was crystallized from DIPE to afford final compound 113 (0.14g; mp.185°C ;Yield= 6%) as a white powder.

15 Fraction 2 (0.14g) was crystallized from Et₂O to afford final compound 114 (0.14g ; mp.210°C ;Yield= 6%) as a white powder.

20

Example B15

Preparation of final compounds 115,
116, 117 and 118




final compound 115 (A diastereoisomer)
final compound 116 (B diastereoisomer)
final compound 117 (A1 enantiomer)
final compound 118 (A2 enantiomer)

nBuLi 1.6M (4.6ml; 0.0074 mol) was added slowly at -20°C under N₂ flow to a solution of *N*-(1-methylethyl)-2-propanamine (1ml; 0.0071 mol) in THF (20ml) . The mixture was cooled to -70°C . A solution of intermediate compound 15 (prepared according to A10) (2g ; 0.0061 mol) in THF (10ml) was added slowly. The mixture was stirred at -70°C for 30 min . A solution of 3-(dimethylamino)-1-(3,5-difluorophenyl)-1-propanone (prepared according to A10) (2g; 0.0094 mol) in THF (15ml) was added slowly . The mixture was stirred at -70°C for 2 hours, then 5 hydrolysed at -30°C with NH₄Cl 10%aq and extracted with EtOAc . The organic layer was separated, dried (MgSO₄), filtered off and the solvent was evaporated . The residue (4.5g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/iPrOH/NH₄OH 99.5/0.5/0.05; 15-40μm) . Two pure fractions were collected and their solvents were evaporated . Fraction 1 (0.67g; Yield=20%) was crystallized 10 from DIPE to afford final compound 115 (0.29g ; mp.192°C ;Yield= 9%) as a white powder. Fraction 2 (0.46g) was crystallized from Et₂O to afford final compound 116 (0.22g ; mp. 224°C ; Yield= 7%) as a white powder. From 0.1g of final compound 115, final compounds 116 and 117 (enantiomers) were separated over CHIRACEL 15 OD (eluent: Heptane/iPrOH 99.9/0.1; 15-40μm). Two fractions were collected and crystallized from Et₂O to afford final compound 116 (0.05g ; mp.161°C ;Yield=100%) as a white powder and final compound 117 (0.043g ; mp158°C ; Yield =98%) as a white powder.

The following final compounds were prepared according to the methods described above :








Table 1 :






5

Comp. nr.	Ex. nr.	R ¹	R ²	R ³	R ⁶	Stereochemistry and melting points
1	B1	Br	OCH ₃	phenyl	H	(A1); 194°C
2	B1	Br	OCH ₃	phenyl	H	(A2); 191°C
3	B1	Br	OCH ₃	phenyl	H	(A); 200°C
4	B1	Br	OCH ₃	phenyl	H	(B); 190°C
16	B1	Br	OCH ₃	4-chlorophenyl	H	(A); 200°C
17	B1	Br	OCH ₃	4-chlorophenyl	H	(B); 190°C
20	B1	Br	OCH ₃	2-thienyl	H	(A); 96°C
21	B1	Br	OCH ₃	2-thienyl	H	(B); 176°C
22	B1	CH ₃	OCH ₃	phenyl	H	(A); 148°C
23	B1	CH ₃	OCH ₃	phenyl	H	(B); 165°C
24	B1	Br	OCH ₃	3-thienyl	H	(A); 162°C
25	B1	Br	OCH ₃	3-thienyl	H	(B); 160°C
26	B1	phenyl	OCH ₃	phenyl	H	(A); 174°C
27	B1	phenyl	OCH ₃	phenyl	H	(B); 192°C
28	B1	F	OCH ₃	phenyl	H	(A); 190°C
29	B1	F	OCH ₃	phenyl	H	(B); 166°C
30	B1	Cl	OCH ₃	phenyl	H	(A); 170°C
31	B1	Cl	OCH ₃	phenyl	H	(B); 181°C
32	B1	Br	SCH ₃	phenyl	H	(A); 208°C
33	B1	Br	SCH ₃	phenyl	H	(B); 196°C
34	B1	OCH ₃	OCH ₃	phenyl	H	(A); 165°C
35	B1	OCH ₃	OCH ₃	phenyl	H	(B); 165°C
36	B1	Br	OCH ₃	phenyl	Cl	(A); 197°C
37	B1	Br	OCH ₃	phenyl	Cl	(B); 221°C


Comp. nr.	Ex. nr.	R ¹	R ²	R ³	R ⁶	Stereochemistry and melting points
38	B9	Br	OCH ₃	3-fluorophenyl	H	(A); 198°C
39	B9	Br	OCH ₃	3-fluorophenyl	H	(B); 207°C
108	B9	Br	OCH ₃	3-fluorophenyl	H	(A1); 160°C
109	B9	Br	OCH ₃	3-fluorophenyl	H	(A2); 156°C
40	B1	H	OCH ₃	phenyl	H	(A); 152°C
41	B1	H	OCH ₃	phenyl	H	(B); 160°C
42	B1	H	OCH ₃	CH ₃	H	(A); 140°C
43	B1	H	OCH ₃	CH ₃	H	(B); 120°C
59	B1	Br	OH	phenyl	H	(A); >260°C
60	B1	Br	OH	phenyl	H	(B); 215°C
5	B2	Br	OCH ₂ CH ₃	phenyl	H	(A); 162°C
6	B2	Br	OCH ₂ CH ₃	phenyl	H	(B); 74°C
7	B3	Br	H	phenyl	H	(A); 98°C
8	B3	Br	H	phenyl	H	(B); 180°C
12	B7	Br	OCH ₃	1-naphthyl	H	(A1); 118°C
13	B7	Br	OCH ₃	1-naphthyl	H	(A2); 120°C
14	B7	Br	OCH ₃	1-naphthyl	H	(A); 210°C
15	B7	Br	OCH ₃	1-naphthyl	H	(B); 244°C
45	B7	Br	OCH ₃	2-naphthyl	H	(A); 262°C
46	B7	Br	OCH ₃	2-naphthyl	H	(B); 162°C
67	B8	Br	OCH ₃	2,5-difluorophenyl	H	(A); 60°C
68	B8	Br	OCH ₃	2,5-difluorophenyl	H	(B); 208°C
110	B8	Br	OCH ₃	2,5-difluorophenyl	H	(A1); 167°C
111	B8	Br	OCH ₃	2,5-difluorophenyl	H	(A2); oil
69	B1	Br	OCH ₃	2-fluorophenyl	H	(A); oil
70	B1	Br	OCH ₃	2-fluorophenyl	H	(B); oil
71	B1	Br	OCH ₃	1-naphthyl	CH ₃	(A); 174°C
72	B1	Br	OCH ₃	1-naphthyl	CH ₃	(B); 178°C
73	B1	Br	OCH ₃	1-naphthyl	Cl	(B); 174°C
74	B1	Br	OCH ₃	1-naphthyl	Cl	(A); 110°C
75	B1	Br	OCH ₃		H	(A); 196°C
76	B1	Br	OCH ₃		H	(B); 130°C

Comp. nr.	Ex. nr.	R ¹	R ²	R ³	R ⁶	Stereochemistry and melting points
77	B1	Br	OCH ₃		H	(A); 202°C
78	B1	Br	OCH ₃		H	(B); 202°C
79	B1	Br		1-naphthyl	H	(A); >250°C
80	B1	Br	OCH ₃	4-cyanophenyl	H	(A); 224°C
81	B1	Br	OCH ₃	4-cyanophenyl	H	(B); 232°C
82	B1	CH ₃	OCH ₃	1-naphthyl	H	(A); 202°C
83	B1	CH ₃	OCH ₃	1-naphthyl	H	(B); 198°C
84	B1	phenyl	OCH ₃	1-naphthyl	H	(A); 248°C
85	B1	phenyl	OCH ₃	1-naphthyl	H	(B); 214°C
86	B1	Br	OCH ₃		H	(A); 184°C
87	B1	Br	OCH ₃		H	(B); 186°C
88	B1	Br	SCH ₃	1-naphthyl	H	(A); 240°C
89	B1	Br	OCH ₃		H	(A); 236°C
90	B1	Br	OCH ₃		H	(B); 206°C
91	B1	H	OCH ₃	1-naphthyl	H	(A); 178°C
92	B1	H	OCH ₃	1-naphthyl	H	(B); 160°C
93	B1	H	OCH ₃	3-fluorophenyl	H	(A); 178°C
94	B1	H	OCH ₃	3-fluorophenyl	H	(B); 182°C
95	B1	Br	OCH ₃	2-phenylethyl	H	(A); 178°C
96	B1	Br	OCH ₃	2-phenylethyl	H	(B); 146°C
97	B1	OCH ₃	OCH ₃	1-naphthyl	H	(A); 168°C
98	B1	OCH ₃	OCH ₃	1-naphthyl	H	(B); 154°C
113	B14	Br	OCH ₃	2,3-difluorophenyl	H	(A); 128°C
114	B14	Br	OCH ₃	2,3-difluorophenyl	H	(B); 213°C
115	B15	Br	OCH ₃	3,5-difluorophenyl	H	(A); 192°C
116	B15	Br	OCH ₃	3,5-difluorophenyl	H	(B); 224°C
117	B15	Br	OCH ₃	3,5-difluorophenyl	H	(A1); 161°C
118	B15	Br	OCH ₃	3,5-difluorophenyl	H	(A2); 158°C
119	B7	Cl	OCH ₃	1-naphthyl	H	(A); 212°C
120	B7	Cl	OCH ₃	1-naphthyl	H	(B); 236°C

Comp. nr.	Ex. nr.	R ¹	R ²	R ³	R ⁶	Stereochemistry and melting points
122	B7	Br	OCH ₃		H	(B); 227°C
127	B7	Br	OCH ₃	5-bromo-2-naphthyl	H	(A); 226°C
130	B7	Br	OCH ₃	5-bromo-2-naphthyl	H	(B); 220°C
131	B1	Br	OCH ₃		H	(A); 206°C
134	B9	OCH ₃	OCH ₃	3-fluorophenyl	H	(A); 172°C
135	B9	OCH ₃	OCH ₃	3-fluorophenyl	H	(B); 182°C
143	B7	Br	OCH ₃	3-bromo-1-naphthyl	H	(A); 234°C
150	B7	Br	OCH ₃	3-bromo-1-naphthyl	H	(B); 212°C
159	B8	Br	OCH ₃	2,5-difluorophenyl	H	(A1); 208°C
160	B8	Br	OCH ₃	2,5-difluorophenyl	H	(A2); 167°C
162	B7	Br	OCH ₃	6-methoxy-2-naphthyl	H	(A); 206°C
163	B7	Br	OCH ₃	6-methoxy-2-naphthyl	H	(B); 206°C
164	B9	Br		3-fluorophenyl	H	(A); 118°C
165	B9	Br		3-fluorophenyl	H	(B); oil
167	B8	Br	OCH ₃	2,6-difluorophenyl	H	(B); 180°C
174	B9		OCH ₃	3-fluorophenyl	H	(A); 159°C
175	B9		OCH ₃	3-fluorophenyl	H	(B); 196°C
176	B7	Br		1-naphthyl	H	(A); oil
179	B9	CN	OCH ₃	3-fluorophenyl	H	(A); 213°C
180	B9	CN	OCH ₃	3-fluorophenyl	H	(B); 163°C
181	B9	Br	OCH ₃	4-fluorophenyl	H	(A); 198°C
182	B9	Br	OCH ₃	4-fluorophenyl	H	(B); 238°C
183	B1	Br	OCH ₃	3-trifluoromethylphenyl	H	(A); 170°C
188	B1	Br	OCH ₃	1,4-pyrimidin-2-yl	H	(A); 110°C

Comp. nr.	Ex. nr.	R ¹	R ²	R ³	R ⁶	Stereochemistry and melting points
189	B1	Br	OCH ₃	1,4-pyrimidin-2-yl	H	(B); 145°C
195	B15	Br	OCH ₃	3,4-difluorophenyl	H	(A); 250°C
196	B15	Br	OCH ₃	3,4-difluorophenyl	H	(B); 184°C
201	B1	Br	OCH ₃		H	(A); 214°C
202	B1	Br	OCH ₃		H	(B); 246°C
203	B9		OCH ₃	3-fluorophenyl	H	(A); 225°C
204	B9		OCH ₃	3-fluorophenyl	H	(B); 216°C
205	B7	Br	OCH ₃	1-naphthyl	F	(A); 213°C
206	B7	Br	OCH ₃	1-naphthyl	F	(B); 213°C
207	B15	F	OCH ₃	3,5-difluorophenyl	H	(A); 232°C
208	B15	F	OCH ₃	3,5-difluorophenyl	H	(B); 188°C
212	B7		OCH ₃	1-naphthyl	H	(B); 220°C

Table 2:




5


Comp. nr.	Ex. nr.	R ¹	R ²	R ³	R ⁴	R ⁵	Phys.data (salt/melting points) and stereochemistry
18	B1	Br	OCH ₃	phenyl	CH ₂ CH ₃	CH ₂ CH ₃	.ethanedioate (2:3); (A); 230°C
19	B1	Br	OCH ₃	phenyl	CH ₂ CH ₃	CH ₂ CH ₃	.ethanedioate (2:3), (B);

Comp. nr.	Ex. nr.	R ¹	R ²	R ³	R ⁴	R ⁵	Phys.data (salt/melting points) and stereochemistry
							150°C
44	B4	Br	OCH ₃	phenyl	H	H	(A); 190°C
9	B4	Br	OCH ₃	phenyl	H	H	(B); 204°C
141	B7	Br	OCH ₃	2-naphthyl	CH ₃	CH ₂ CH ₃	(A); 188°C
142	B7	Br	OCH ₃	2-naphthyl	CH ₃	CH ₂ CH ₃	(B); 202°C
230	B12	Br	OCH ₃	1-naphthyl	CH ₃	benzyl	/oil
147	B7	Br	OCH ₃	1-naphthyl	CH ₃	CH ₂ CH ₃	(A); 168°C
148	B7	Br	OCH ₃	1-naphthyl	CH ₃	CH ₂ CH ₃	(B); 212°C
56	B13	Br	OCH ₃	1-naphthyl	CH ₃	H	(A); 204°C
214	B13	Br	OCH ₃	1-naphthyl	CH ₃	H	(B); 225°C


Table 3:




Comp. nr.	Ex. nr.	R ³	L	Stereochemistry and melting points
47	B1	phenyl	1-piperidinyl	(A); 190°C
48	B1	phenyl	1-piperidinyl	(B); 210°C
128	B1	2-naphthyl	1-piperidinyl	(A); 254°C
129	B1	2-naphthyl	1-piperidinyl	(B); 212°C
49	B1	phenyl	1-imidazolyl	(A); 216°C
50	B1	phenyl	1-imidazolyl	(B); 230°C
51	B1	phenyl	1-(4-methyl)piperazinyl	(A); 150°C
52	B1	phenyl	1-(4-methyl)piperazinyl	(B); 230°C
53	B1	phenyl	1-(1,2,4-triazolyl)	(A); 180°C



Comp. nr.	Ex. nr.	R ³	L	Stereochemistry and melting points
54	B1	phenyl	1-(1,2,4-triazolyl)	(B); 142°C
55	B1	phenyl	thiomorpholinyl	(A); oil
57	B5	phenyl		(A); 244°C
10	B5	phenyl		(B); 198°C
58	B6	phenyl		(A); 208°C
11	B6	phenyl		(B); 208°C
99	B11	1-naphthyl		(A1); 218°C
100	B6	1-naphthyl		(A2); 218°C
101	B6	1-naphthyl		(B); 175°C
102	B5	1-naphthyl		(A2); 210°C




Comp. nr.	Ex. nr.	R ³	L	Stereochemistry and melting points
103	B5	1-naphthyl		(B); >250°C
121	B5	1-naphthyl		(A1); 210°C
123	B1	phenyl	morpholiny1	(A); 226°C
124	B1	phenyl	morpholiny1	(B); 210°C
136	B7	2-naphthyl	4-methylpyrazinyl	(A); 188°C
137	B7	2-naphthyl	4-methylpyrazinyl	(B); 232°C
139	B7	2-naphthyl	morpholiny1	(A); 258°C
140	B7	2-naphthyl	morpholiny1	(B); 214°C
144	B7	2-naphthyl	pyrrolidiny1	(A); 238°C
145	B7	1-naphthyl	1-piperidiny1	(A); 212°C
146	B7	1-naphthyl	1-piperidiny1	(B); 220°C
149	B7	1-naphthyl	4-methylpyrazinyl	(B); 232°C
151	B7	3-bromo-1-naphthyl	4-methylpiperazinyl	(A); 178°C
152	B7	3-bromo-1-naphthyl	4-methylpiperazinyl	(B); 226°C
153	B7	6-bromo-2-naphthyl	4-methylpiperazinyl	(A); 208°C
154	B7	6-bromo-2-naphthyl	4-methylpiperazinyl	(B); 254°C
155	B7	6-bromo-2-naphthyl	1-piperidiny1	(A); 224°C
156	B7	1-naphthyl	4-methylpiperazinyl	(A); 200°C
157	B7	6-bromo-2-naphthyl	1-pyrrolidiny1	(B); 220°C
158	B7	1-naphthyl	morpholiny1	(B); 272°C
166	B7	6-bromo-2-naphthyl	1-piperidiny1	(B); 218°C
170	B7	2-naphthyl	1-pyrrolidiny1	(A); 238°C
171	B7	2-naphthyl	1-pyrrolidiny1	(B); 218°C




Comp. nr.	Ex. nr.	R ³	L	Stereochemistry and melting points
172	B7	1-naphthyl	1,2,4-triazol-1-yl	/142°C
173	B7	1-naphthyl	1,2-imidazol-1-yl	(A); 222°C
177	B7	6-bromo-2-naphthyl	morpholinyl	(A); 242°C
178	B7	6-bromo-2-naphthyl	morpholinyl	(B); 246°C
187	B7	1-naphthyl	1,2-imidazol-1-yl	(B); 236°C
200	B7	2-naphthyl		(A); 254°C
209	B7	2-naphthyl		(B); 198°C

Table 4:




Comp. nr.	Ex. nr.	R ³	Q	L	Stereochemistry and melting points
61	B1	phenyl	0	N(CH ₃) ₂	(A); 220°C
62	B1	phenyl	0	N(CH ₃) ₂	(B); 194°C
63	B1	phenyl	2	N(CH ₃) ₂	(A); 150°C
64	B1	phenyl	2	N(CH ₃) ₂	(B); 220°C
125	B7	2-naphthyl	2	N(CH ₃) ₂	(A); 229°C
126	B7	2-naphthyl	2	N(CH ₃) ₂	(B); 214°C
65	B1	phenyl	3	N(CH ₃) ₂	(A); 130°C




Comp. nr.	Ex. nr.	R ³	Q	L	Stereochemistry and melting points
66	B1	phenyl	3	N(CH ₃) ₂	(B); 170°C
132	B7	2-naphthyl	2	pyrrolidinyl	(A); 227°C
133	B7	2-naphthyl	2	pyrrolidinyl	(B); 222°C
161	B7	2-naphthyl	2	morpholinyl	(B); 234°C
186	B7	1-naphthyl	2	N(CH ₃) ₂	(A); 187°C
190	B7	2-naphthyl	3	N(CH ₃) ₂	(A); 170°C
191	B7	2-naphthyl	3	N(CH ₃) ₂	(B); 145°C
192	B7	2-naphthyl	2	N(CH ₂ CH ₃) ₂	(A); 90°C
193	B7	2-naphthyl	2	N(CH ₂ CH ₃) ₂	(B); 202°C
194	B7	1-naphthyl	2	pyrrolidinyl	(B); 206°C
197	B7	1-naphthyl	3	N(CH ₃) ₂	(A); 160°C
198	B7	2-naphthyl	2	morpholinyl	(A); 215°C
199	B7	1-naphthyl	2	N(CH ₂ CH ₃) ₂	(A); 185°C
210	B7	1-naphthyl	2	morpholinyl	(B); 222°C
211	B7	1-naphthyl	2	morpholinyl	(A); 184°C

Table 5:




Comp. nr.	Ex. nr.	R ³	R ⁸	R ⁹	Stereochemistry and melting points
104	B1	phenyl	-CH=CH-N=		(A); 170°C
105	B1	phenyl	-CH=CH-N=		(B); 150°C




Comp. nr.	Ex. nr.	R ³	R ⁸	R ⁹	Stereochemistry and melting points
106	B1	phenyl	CH ₃	=O	(A); 224°C
107	B1	phenyl	CH ₃	=O	(B); 180°C
138	B7	1-naphthyl	H	=O	(A1); >260°C

Table 6:



Comp. nr.	Ex. nr.	R ¹				R ³	R ⁶	Stereochemistry and melting points
		a	b	c	d			
215	B9	H	Br	CH ₃	H	3-fluorophenyl	H	(A); 197°C
216	B9	H	Br	CH ₃	H	3-fluorophenyl	H	(B); 158°C
217	B7	H	H	Br	H	1-naphthyl	H	(A); 212°C
218	B7	H	H	Br	H	1-naphthyl	H	(B); 172°C
219	B9	H	Br	H	CH ₃	3-fluorophenyl	H	(A); 220°C
220	B9	H	Br	H	CH ₃	3-fluorophenyl	H	(B); 179°C
221	B7	Br	H	H	H	1-naphthyl	H	(A); 170°C
224	B7	Br	H	H	H	1-naphthyl		/205°C
222	B7	H	Br	H	H	1-naphthyl		(A); 155°C
223	B7	H	Br	H	H	1-naphthyl		(B); 205°C



Comp. nr.	Ex. nr.	R¹				R³	R⁶	Stereochimistry and melting points
		a	b	c	d			
225	B7	H	Br	CH ₃	H	1-naphthyl	H	(A); 238°C
226	B7	H	Br	CH ₃	H	1-naphthyl	H	(B); 208°C
227	B15	H	Br	CH ₃	H	3,5-difluorophenyl	H	(A); 195°C
228	B15	H	Br	CH ₃	H	3,5-difluorophenyl	H	(B); 218°C
229	B7	H	CH ₃	CH ₃	H	1-naphthyl	H	(A); 238°C

C. Pharmacological examples

C.1. In-vitro method for testing compounds against *M. tuberculosis*.

5

Flat-bottom, sterile 96-well plastic microtiter plates were filled with 100 µl of Middlebrook (1x) broth medium. Subsequently, stock solutions (10 x final test concentration) of compounds were added in 25 µl volumes to a series of duplicate wells in column 2 so as to allow evaluation of their effects on bacterial growth. Serial five-fold dilutions were made directly in the microtiter plates from column 2 to 11 using a customised robot system (Zymark Corp., Hopkinton, MA). Pipette tips were changed after every 3 dilutions to minimize pipetting errors with high hydrophobic compounds. Untreated control samples with (column 1) and without (column 12) inoculum were included in each microtiter plate. Approximately 5000 CFU per well of *Mycobacterium tuberculosis* (strain H37RV), in a volume of 100 µl in Middlebrook (1x) broth medium, was added to the rows A to H, except column 12. The same volume of broth medium without inoculum was added to column 12 in row A to H. The cultures were incubated at 37°C for 7 days in a humidified atmosphere (incubator with open air valve and continuous ventilation). One day before the end of incubation, 6 days after inoculation, Resazurin (1:5) was added to all wells in a volume of 20 µl and plates were incubated for another 24 hours at 37°C. On day 7 the bacterial growth was quantitated fluorometrically.

The fluorescence was read in a computer-controlled fluorometer (Spectramax Gemini EM, Molecular Devices) at an excitation wavelength of 530 nm and an emission wavelength of 590 nm. The percentage growth inhibition achieved by the compounds was calculated according to standard methods, and MIC data (representing IC90's expressed in microgram/ml) were calculated. The results are shown in Table 5.

C.2. In-vitro method for testing compounds for anti-bacterial activity against strain M. Smegmatis ATCC607.

10 Flat-bottom, sterile 96-well plastic microtiter plates were filled with 180 μ l of sterile deionized water, supplemented with 0.25 % BSA. Subsequently, stock solutions (7.8 x final test concentration) of compounds were added in 45 μ l volumes to a series of duplicate wells in column 2 so as to allow evaluation of their effects on bacterial growth. Serial five-fold dilutions (45 μ l in 180 μ l) were made directly in the microtiter plates from column 2 to 11 using a customised robot system (Zymark Corp., Hopkinton, MA). Pipette tips were changed after every 3 dilutions to minimize pipetting errors with high hydrophobic compounds. Untreated control samples with (column 1) and without (column 12) inoculum were included in each microtiter plate. Approximately 250 CFU per well of bacteria inoculum, in a volume of 100 μ l in 2.8x 15 Mueller-Hinton broth medium, was added to the rows A to H, except column 12. The same volume of broth medium without inoculum was added to column 12 in row A to H. The cultures were incubated at 37°C for 48 hours in a humidified 5% CO₂ atmosphere (incubator with open air valve and continuous ventilation). At the end of incubation, two days after inoculation, the bacterial growth was quantitated 20 fluorometrically. Therefore Alamar Blue (10x) was added to all wells in a volume of 20 μ l and plates were incubated for another 2 hours at 50°C.

25 The fluorescence was read in a computer-controlled fluorometer (Cytofluor, Biosearch) at an excitation wavelength of 530 nm and an emission wavelength of 590 nm (gain 30). The % growth inhibition achieved by the compounds was calculated according to standard methods. The pIC₅₀ was defined as the 50 % inhibitory concentration for bacterial growth. The results are shown in Table 5.

Table 5 : Results of an in vitro-screening of the compounds according to the invention for *M. tuberculosis* (MIC) and *M. smegmatis* (pIC₅₀).

Co.No.	MIC	pIC ₅₀
118	0.01	9.1
174	0.06	6.8
12	0.07	8.7
115	0.07	8.6
69	0.13	8.5
71	0.14	8.5
113	0.27	8.6
5	0.33	7.8
32	0.33	7.4
109	0.33	8.2
16	0.34	6.8
37	0.34	7.9
67	0.34	8.6
110	0.34	8.5
164	0.36	7.9
183	0.36	8.3
208	0.38	7.9
98	0.51	7.9
216	0.85	8.0
26	1.00	7.2
22	1.11	7.2
203	1.15	8.0
28	1.41	7.3
30	1.46	7.8
179	1.48	7.0
135	1.50	7.4
91	1.51	7.5
188	1.60	7.2
24	1.62	7.2
63	1.64	6.7
65	1.69	5.7
66	1.69	4.7
17	1.71	6.5
111	1.71	6.4
117	1.71	6.7
196	1.71	6.6
75	1.74	7.9
76	1.74	5.9
45	1.76	8.0
46	1.76	6.4

Co.No.	MIC	pIC ₅₀
227	1.76	7.5
94	1.77	7.9
225	1.80	6.6
35	1.82	6.8
190	1.85	6.5
191	1.85	6.5
80	2.11	7.1
102	2.21	6.5
121	2.21	5.9
165	2.26	6.6
79	2.43	7.2
15	2.78	6.5
72	3.59	6.9
180	3.73	6.6
82	3.90	7.1
205	4.56	7.2
36	5.40	6.4
103	5.54	5.9
192	5.98	6.5
44	6.01	5.9
64	6.54	5.8
19	6.72	6.5
195	6.82	6.5
52	7.06	6.4
172	7.30	5.7
31	7.31	5.8
134	7.52	6.5
92	7.55	6.5
83	7.78	5.8
62	7.79	5.9
27	7.97	5.9
6	8.23	5.8
33	8.27	6.0
38	8.30	7.9
39	8.30	6.1
181	8.30	6.9
182	8.30	6.3
41	8.51	5.9
215	8.52	6.2
220	8.52	5.3
116	8.58	6.6
138	8.58	6.6
47	8.65	6.5
48	8.65	5.8
84	8.76	7.0

Co.No.	MIC	pIC ₅₀
85	8.76	5.9
23	8.79	6.4
14	8.80	6.8
218	8.80	6.6
228	8.80	5.1
77	8.93	7.2
141	9.03	7.3
142	9.03	6.2
226	9.03	5.5
99	9.06	7.9
101	9.06	5.8
212	9.08	6.0
206	9.09	6.5
204	9.14	5.4
197	9.25	6.6
162	9.28	7.0
193	9.47	5.6
176	9.50	6.8
156	9.68	5.3
201	9.77	5.7
175	10.19	6.5
119	10.20	7.8
10	10.26	5.6
18	10.60	6.7
152	10.93	5.8
147	11.36	7.4
151	13.76	5.0
86	16.02	6.9
21	16.17	5.4
58	16.49	6.8
136	16.81	6.2
95	16.87	6.9
125	18.01	4.4
97	20.17	5.9
25	20.36	5.2
96	21.24	6.2
40	21.38	4.7
73	23.49	8.0
8	23.83	5.7
127	25.26	6.9
189	25.43	5.5
57	25.77	5.4
222	30.35	8.0
93	35.31	4.8
9	37.92	4.5


Co.No.	MIC	pIC ₅₀
61	39.04	4.5
229	40.09	7.1
87	40.23	5.0
120	40.60	5.9
20	40.63	5.9
11	41.42	4.6
81	42.14	5.4
137	42.23	4.6
219	42.69	5.8
56	43.01	7.2
114	43.01	5.9
167	43.01	5.5
13	44.13	6.7
107	44.13	5.8
217	44.13	6.9
221	44.13	6.5
224	44.13	4.9
42	44.34	6.3
43	44.34	4.4
131	44.45	6.9
29	44.46	5.9
78	44.76	5.8
55	44.77	5.1
88	45.40	6.8
100	45.40	7.1
34	45.66	5.1
170	46.19	5.6
171	46.19	4.3
163	46.51	5.9
129	47.31	4.7
132	47.31	4.4
194	47.31	4.9
199	47.47	6.5
7	47.54	4.6
207	48.05	5.2
149	48.50	5.1
202	48.98	4.8
130	50.32	5.3
143	50.39	6.9
70	52.35	5.8
144	52.46	7.0
157	52.46	5.6
49	52.85	5.4
50	52.85	5.0
53	52.94	5.1

Co.No.	MIC	pIC ₅₀
54	52.94	4.1
112	54.15	5.5
123	54.75	4.2
124	54.75	5.3
153	54.77	5.3
106	55.55	6.2
126	56.96	5.2
148	56.96	4.9
186	56.96	4.5
173	57.85	4.7
187	57.85	4.0
122	58.16	4.8
74	59.00	6.5
89	59.06	6.4
90	59.06	5.3
128	59.56	4.0
133	59.56	5.1
145	59.56	5.3
146	59.56	4.8
139	59.76	4.1
140	59.76	5.8
158	59.76	5.3
223	60.56	5.7
161	61.16	4.0
198	61.16	4.3
210	61.16	6.1
211	61.16	4.1
150	63.44	5.7
155	67.45	4.9
166	67.45	4.1
200	67.47	4.9
209	67.47	4.0
177	67.65	4.0
178	67.65	4.5
154	68.95	4.9
1	n.d.	7.3
2	n.d.	6.8
3	n.d.	6.7
4	n.d.	5.7
51	n.d.	5.8
59	n.d.	5.1
60	n.d.	5.6
68	n.d.	6.4
104	n.d.	6.6
105	n.d.	6.0


Co.No.	MIC	pIC ₅₀
108	n.d.	7.0

CLAIMS

1. A compound according to the general Formula (Ia) or the general Formula (Ib)



5



the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, wherein :


10 R¹ is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ;

p is an integer equal to zero, 1, 2, 3 or 4 ;

R^2 is hydrogen, hydroxy, thio, alkyloxy, alkyloxyalkyloxy, alkylthio, mono

CCN(CC)CC

or di(alkyl)amino or a radical of formula



wherein Y is CH_2 ,

15 O, S, NH or N-alkyl ;

R^3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl;

q is an integer equal to zero, 1, 2, 3 or 4 ;

R^4 and R^5 each independently are hydrogen, alkyl or benzyl; or

R⁴ and R⁵ together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, 2H-pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, 5 piperazinyl, imidazolidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, amino, mono- or dialkylamino, alkylthio, alkyloxyalkyl, alkylthioalkyl and pyrimidinyl ;

R⁶ is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, 10 alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ; or two vicinal R⁶ radicals may be taken together to form a bivalent radical of formula =C-C=C=C- ;

r is an integer equal to 0, 1, 2, 3, 4 or 5 ; and

R⁷ is hydrogen, alkyl, Ar or Het ;

15 R⁸ is hydrogen or alkyl ;

R⁹ is oxo ; or

R⁸ and R⁹ together form the radical =N-CH=CH- .

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with halo, hydroxy, alkyloxy or oxo ;

20 Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl ;

25 Het is a monocyclic heterocycle selected from the group of N-phenoxy piperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thieryl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl ; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, 30 benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]dioxolyl ; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 substituents selected from the group of halo, hydroxy, alkyl or alkyloxy ;

35


halo is a substituent selected from the group of fluoro, chloro, bromo and iodo and
 haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6
 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6
 carbon atoms, wherein one or more carbon atoms are substituted with one or
 5 more halo-atoms.

2. A compound according to claim 1, characterized in that

10 R^1 is hydrogen, halo, cyano, Ar, Het, alkyl, and alkyloxy ;

p is an integer equal to zero, 1, 2, 3 or 4 ;

15 R^2 is hydrogen, hydroxy, alkyloxy, alkyloxyalkyloxy, alkylthio or a radical



R^3 is alkyl, Ar, Ar-alkyl or Het ;

q is an integer equal to zero, 1, 2, or 3 ;

R^4 and R^5 each independently are hydrogen, alkyl or benzyl; or

15 R^4 and R^5 together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, imidazolyl, triazolyl, piperidinyl, piperazinyl, pyrazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl and pyrimidinyl ;

R^6 is hydrogen, halo or alkyl ; or

20 two vicinal R^6 radicals may be taken together to form a bivalent radical of formula
 $=C-C=C=C-$;

r is an integer equal to 1 ; and

R^7 is hydrogen ;

R^8 is hydrogen or alkyl ;

25 R^9 is oxo ; or

R^8 and R^9 together form the radical $=N-CH=CH-$.

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with halo or hydroxy ;

30 Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, haloalkyl, cyano, alkyloxy and morpholinyl ;

Het is a monocyclic heterocycle selected from the group of N-phenoxy piperidinyl, furanyl, thienyl, pyridinyl, pyrimidinyl ; or a bicyclic heterocycle selected from the group of benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]-dioxolyl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 alkyl substituents ; and
halo is a substituent selected from the group of fluoro, chloro and bromo.

3. A compound according to any one of claims 1 and 2, characterized in that, independently from each other, R¹ is hydrogen, halo, Ar, alkyl or alkyloxy, p = 1, R² is hydrogen, alkyloxy or alkylthio, R³ is naphthyl, phenyl or thienyl, each optionally substituted with 1 or 2 substituents selected from the group of halo and haloalkyl, q = 0, 1, 2 or 3, R⁴ and R⁵ each independently are hydrogen or alkyl or R⁴ and R⁵ together and including the N to which they are attached form a radical selected from the group of imidazolyl, triazolyl, piperidinyl, piperazinyl and thiomorpholinyl, R⁶ is hydrogen, alkyl or halo, r is equal to 0 or 1 and R⁷ is hydrogen.
4. A compound according to claim 3, characterized in that, independently from each other, R¹ is bromo, R² is alkyloxy, R³ is naphthyl or phenyl, q=1, R⁴ and R⁵ each independently are hydrogen, methyl or ethyl and R⁶ is hydrogen.
5. A compound which is degraded in vivo to yield a compound according to any one of claims 1 to 4.
6. A compound according to claim 1, characterized in that the compound is :
 - 25 ○ 1-(6-bromo-2-methoxy-quinolin-3-yl)-2-(3,5-difluoro-phenyl)-4-dimethylamino-1-phenyl-butan-2-ol ;
 - 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol ;
 - 1-(6-bromo-2-methoxy-quinolin-3-yl)-2-(2,5-difluoro-phenyl)-4-dimethylamino-1-phenyl-butan-2-ol ;
 - 1-(6-bromo-2-methoxy-quinolin-3-yl)-2-(2,3-difluoro-phenyl)-4-dimethylamino-1-phenyl-butan-2-ol ;
 - 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-(2-fluoro-phenyl)-1-phenyl-butan-2-ol ;
 - 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol ;
 - 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol ; and

- 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-(3-fluoro-phenyl)-1-phenyl-butan-2-ol,
the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof.

5


7. A compound according to any one of claims 1 to 6 for use as a medicine.

8. A composition comprising a pharmaceutically acceptable carrier and, as active 10 ingredient, a therapeutically effective amount of a compound as defined in any one of claims 1 to 7.

9. Use of a compound according to any one of claims 1 to 7 or a composition according to 15 claim 8 for the manufacture of a medicament for the treatment of mycobacterial diseases.

10. Method of treating a patient suffering from, or at risk of, a mycobacterial disease, which comprises administering to the patient a therapeutically effective amount of a compound according to any one of claims 1 to 7 or pharmaceutical composition 20 according to claim 8.

11. A process for preparing a compound according to any one of claims 1 to 7, characterized in that a compound of Formula (II) is reacted with a compound of Formula (III) according to the following reaction :



wherein R^1 , p , R^2 , R^3 , q , R^4 , R^5 , R^6 and R^7 are defined as in Formula (Ia).

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/50322

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C07D215/22	A61K31/47	A61P31/06	C07D409/06	C07D215/36
	C07D405/06	C07D401/06	C07D405/04	C07D215/48	C07D409/04
	C07D401/12	C07D471/04	//(C07D471/04, 235:00, 221:00)		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 34265 A (SEPRACOR INC.) 15 June 2000 (2000-06-15) cited in the application page 7, line 11 – line 21; claims ---	1,8,9
A	US 5 965 572 A (WILLIAM Y. ELLIS ET AL.) 12 October 1999 (1999-10-12) cited in the application claims ---	1,8,9
A	WO 99 37635 A (SMITHKLINE BEECHAM PLC) 29 July 1999 (1999-07-29) claims ---	1,8

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

18 November 2003

Date of mailing of the international search report

28/11/2003

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/50322

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 10 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of Invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/50322

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 0034265	A 15-06-2000	US AU WO US	6103905 A 1933500 A 0034265 A2 6376670 B1	15-08-2000 26-06-2000 15-06-2000 23-04-2002
US 5965572	A 12-10-1999	US US EP JP WO	6274598 B1 2002115678 A1 0936866 A1 2001503411 T 9818326 A1	14-08-2001 22-08-2002 25-08-1999 13-03-2001 07-05-1998
WO 9937635	A 29-07-1999	AU CA DE WO EP JP ZA	2717899 A 2318842 A1 69908555 D1 9937635 A1 1051413 A1 2002501061 T 9900520 A	09-08-1999 29-07-1999 10-07-2003 29-07-1999 15-11-2000 15-01-2002 25-07-2000

PATENT COOPERATION TREATYWO 2006/135649
PCT/US2006/022195

From the INTERNATIONAL BUREAU

PCT**NOTIFICATION CONCERNING
AVAILABILITY OF THE PUBLICATION
OF THE INTERNATIONAL APPLICATION**Date of mailing (*day/month/year*)
15 February 2007 (15.02.2007)

To:

JOHNSON, Philip, S.
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
ETATS-UNIS D'AMERIQUEApplicant's or agent's file reference
PRD2400WOPCT**IMPORTANT NOTICE**International application No.
PCT/US2006/022195International filing date (*day/month/year*)
07 June 2006 (07.06.2006)Priority date (*day/month/year*)
10 June 2005 (10.06.2005)

Applicant

JANSSEN PHARMACEUTICA N.V. et al

The applicant is hereby notified that the International Bureau:

has published the above-indicated international application on under
No. WO
No. WO 2006/135649

has republished the above-indicated international application on 15 February 2007 (15.02.2007) under
No. WO 2006/135649
For an explanation as to the reason for this republication of the international application, reference is made to INID codes (15), (48) or (88) (*as the case may be*) on the front page of the published international application.

A copy of the international application is available for viewing and downloading on WIPO's website at the following address:
<http://www.wipo.int/pctdb> (under "Query" enter the PCT or WO number).

The applicant may also request a paper copy of the published international application from the International Bureau by submitting a written request to PatentScope@wipo.int or to the address provided below.

RECEIVED

MAR 05 2007

J&J PAT. DKT. SECTION

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Philippe Becamel

Facsimile No. +41 22 338 82 70

e-mail: pt12.pct@wipo.int